Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chiasma Looks Ahead To First Approval With "Revolutionary" Technology Opportunity

This article was originally published in The Pink Sheet Daily

Executive Summary

Anticipating an April 15 user fee date for oral ocreotide for acromegaly, Chiasma thinks its platform technology to make peptides orally available can offer substantial opportunities for therapeutic optionality.

You may also be interested in...



FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized

Office of Prescription Drug Promotion seemed to expand its focus in issuing 11 letters last year.

CMS-Manufacturer Discussion Of Medicare Price Negotiation Program Scheduled For 13 December

Agency reaches out to manufacturers as it develops its approach to implementing the controversial new program.

Minute Insight: Activ Surgical Wins CE Mark For ActivSight

After winning US FDA clearance in 2021, Activ Surgical now also received the green light to market its visualization module for surgeons in Europe. 

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS079236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel